Program
aflibercept
Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 251 open or running | phase 4since Nov 2, 2012 | May 13, 2002 | none ahead |
| Bayer | 230 open or running | phase 4since Apr 10, 2014 | Mar 12, 2008 | none ahead |
| Sanofi | 200 open or running | phase 3since May 16, 2006 | Jan 30, 2006 | none ahead |
| Novartis | 40 open or running | phase 4since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Amgen | 31 open or running | phase 3since Feb 13, 2020 | Feb 13, 2020 | Jul 31, 2027phase 3 · NCT07614776 |
| Sam Chun Dang Pharm. | 20 open or running | phase 3since Jul 17, 2020 | Jul 17, 2020 | none ahead |
| AbbVie | 11 open or running | phase 2since Mar 16, 2022 | Mar 16, 2022 | Jun 2031phase 2 · NCT05296447 |
| AO GENERIUM | 11 open or running | phase 3since Sep 18, 2026 | Sep 18, 2026 | May 2028phase 3 · NCT07844148 |
| bioeq-gmbh | 10 open or running | phase 3since Aug 11, 2020 | Aug 11, 2020 | none ahead |
| cinnagen | 10 open or running | phase 3since Sep 18, 2022 | Sep 18, 2022 | none ahead |
| Exegenesis Bio | 11 open or running | phase 1since Jan 30, 2025 | Jan 30, 2025 | Feb 2029phase 1 · NCT06817343 |
| formycon-ag | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Qilu Pharmaceutical | 10 open or running | phase 3since Apr 19, 2022 | Apr 19, 2022 | none ahead |
| Samsung Bioepis | 10 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | none ahead |
| the-emmes-company-llc | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
Also a collaborator on its studies: regenxbio-inc and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 10, 2009.
- Aug 19, 2022Phase 4 study in Diabetic Macular EdemaBayer · NCT05511038 · 100 enrolled · India
- Sep 18, 2022cinnagen's first study: phase 3 study in Macular DegenerationNew to cinnagencinnagen · NCT05587062 · 168 enrolled · Iran, Islamic Republic of
- Jan 20, 2023Phase 3 study in Chorioretinal Vascular DiseaseAmgen · NCT05704725 · 49 enrolled · United States
- Apr 28, 2023Phase 3 study in Macular Edema Secondary to Retinal Vein OcclusionBayer · NCT05850520 · 892 enrolled · United States, Australia, Austria and more
- Aug 3, 2023Phase 3 study in Diabetic Macular Edema (DME)Regeneron Pharmaceuticals · NCT05989126 · 35 enrolled · United States
- May 15, 2024Phase 3 study in Diabetic Macular EdemaBayer · NCT06422507 · 333 enrolled · China, Hong Kong
- Jul 1, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationRegeneron Pharmaceuticals · NCT06491914 · 1,126 enrolled · United States, Puerto Rico
- Sep 8, 2024Phase 4 study in Diabetic Macular EdemaBayer · NCT06591598 · 51 enrolled · Czechia, Hungary, Slovakia
- Nov 25, 2024formycon-ag's first study: phase 4 study in Macular DegenerationNew to formycon-agformycon-ag · NCT06708637 · 30 enrolled · United States
- Jan 30, 2025Exegenesis Bio's first study: phase 1 study in Macular DegenerationNew to Exegenesis BioExegenesis Bio · NCT06817343 · 12 enrolled · United States
- Mar 24, 2026Phase 2 study in Macular DegenerationSam Chun Dang Pharm. · NCT07501052 · 33 enrolled · United States
- May 22, 2026Phase 3 study in Neovascular Age-related Macular DegenerationAmgen · NCT07614776 · 304 planned · United States, Czechia, Hungary and more
- Sep 18, 2026AO GENERIUM's first study: phase 3 study in nAMDNew to AO GENERIUMAO GENERIUM · NCT07844148 · 180 planned · Russia
- Sep 21, 2026Samsung Bioepis's first study: phase 2 study in Neovascular Age-related Macular DegenerationNew to Samsung BioepisSamsung Bioepis · NCT07844343 · 33 enrolled · South Korea
Ahead
- Jul 31, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationAmgen · NCT07614776
- May 2028Primary completion: phase 3 study in nAMDAO GENERIUM · NCT07844148
- Feb 2029Primary completion: phase 1 study in Macular DegenerationExegenesis Bio · NCT06817343
- Jun 2031Primary completion: phase 2 study in Diabetic RetinopathyAbbVie · NCT05296447
TargetBeta
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 86 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07844343Neovascular Age-related Macular Degeneration · South Korea | 2 | Completed | Samsung Bioepis | Sep 22, 2026 | 33 |
| NCT07844148nAMD · Russia | 3 | Recruiting | AO GENERIUM | May 2028 | 180 |
| NCT07614776Neovascular Age-related Macular Degeneration · United States, Czechia, Hungary and more | 3 | Recruiting | Amgen | Jul 31, 2027 | 304 |
| NCT07501052Macular Degeneration · United States | 2 | Completed | Sam Chun Dang Pharm. | May 27, 2026 | 33 |
| NCT06817343Macular Degeneration · United States | 1 | Active, not recruiting | Exegenesis Bio | Feb 2029 | 12 |
| NCT06708637Macular Degeneration · United States | 4 | Completed | formycon-ag | Oct 8, 2024 | 30 |
| NCT06591598Diabetic Macular Edema · Czechia, Hungary, Slovakia | 4 | Completed | Bayer | Oct 14, 2025 | 51 |
| NCT06491914Neovascular Age-Related Macular Degeneration · United States, Puerto Rico | 3 | Active, not recruiting | Regeneron Pharmaceuticals | Aug 26, 2025 | 1,126 |
| NCT06422507Diabetic Macular Edema · China, Hong Kong | 3 | Completed | Bayer | Dec 29, 2025 | 333 |
| NCT05989126Diabetic Macular Edema (DME) · United States | 3 | Completed | Regeneron Pharmaceuticals | May 31, 2024 | 35 |
| NCT05850520Macular Edema Secondary to Retinal Vein Occlusion · United States, Australia, Austria and more | 3 | Completed | Bayer | Nov 7, 2024 | 892 |
| NCT05704725Chorioretinal Vascular Disease · United States | 3 | Completed | Amgen | Feb 17, 2023 | 49 |
| NCT05587062Macular Degeneration · Iran, Islamic Republic of | 3 | Completed | cinnagen | Jul 31, 2022 | 168 |
| NCT05511038Diabetic Macular Edema · India | 4 | Completed | Bayer | Apr 16, 2024 | 100 |
| NCT05473715Macular Degeneration · Canada, United Kingdom | 4 | Terminated | Bayer | Jul 11, 2023 | 3 |
| NCT05345236Wet Age-related Macular Degeneration · China | 3 | Completed | Qilu Pharmaceutical | Jan 25, 2022 | 366 |
| NCT05296447Diabetic Retinopathy · United States | 2 | Active, not recruiting | AbbVie | Jun 2031 | 103 |
| NCT05282004Neovascular Age-related Macular Degeneration (nAMD) · United States | 3 | Completed | Novartis | Sep 7, 2022 | 36 |
| NCT05161806Neovascular Age-related Macular Degeneration (nAMD) · United States | 3 | Completed | Novartis | May 4, 2022 | 30 |
| NCT04864834Neovascular Age-related Macular Degeneration · United States, Australia, Austria and more | 3 | Completed | Novartis | Jul 7, 2022 | 485 |
| NCT04522167Neovascular Age-related Macular Degeneration · Bulgaria, Czechia, Hungary and more | 3 | Completed | bioeq-gmbh | Jun 23, 2022 | 434 |
| NCT04480463Macular Degeneration · United States, Australia, Bulgaria and more | 3 | Completed | Sam Chun Dang Pharm. | Sep 8, 2022 | 576 |
| NCT04429503Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more | 3 | Completed | Regeneron Pharmaceuticals | May 30, 2022 | 660 |
| NCT04270747Macular Degeneration · United States, Canada, Czechia and more | 3 | Completed | Amgen | Jul 18, 2022 | 576 |
| NCT04126317Macular Degeneration · United States, Puerto Rico | 2 | Completed | Regeneron Pharmaceuticals | May 14, 2021 | 106 |
| NCT04101721Retinopathy of Prematurity · United States, Bulgaria, Colombia and more | 3 | Completed | Regeneron Pharmaceuticals | Aug 18, 2022 | 127 |
| NCT04015180Retinopathy of Prematurity · Argentina, Belgium, Brazil and more | 3 | Completed | Bayer | Sep 19, 2025 | 100 |
| NCT04004208Retinopathy of Prematurity · Argentina, Austria, Belgium and more | 3 | Completed | Bayer | Feb 12, 2021 | 113 |
| NCT03767738Chorioretinal Vascular Disease · United States | 4 | Completed | Regeneron Pharmaceuticals | Aug 19, 2020 | 65 |
| NCT03639675Glaucoma, Neovascular · Japan | 3 | Completed | Bayer | Feb 14, 2019 | 16 |
| NCT02878681Visual Impairment Due to Diabetic Macular Edema | 4 | Withdrawn | Novartis | Sep 2017 | 0 |
| NCT02818998Macular Edema · Austria, Canada, Czechia and more | 3 | Completed | Bayer | Nov 13, 2018 | 463 |
| NCT02800642Retinal Vein Occlusion · Australia, Canada, Denmark and more | 4 | Completed | Bayer | Jul 31, 2019 | 162 |
| NCT02718326Nonproliferative Diabetic Retinopathy · United States, Germany, Hungary and more | 3 | Completed | Regeneron Pharmaceuticals | Aug 6, 2018 | 402 |
| NCT02712008Diabetic Macular Edema · United States | 2 | Completed | Regeneron Pharmaceuticals | Jul 10, 2017 | 302 |
| NCT02581995Macular Edema · Austria, Canada, Czechia and more | 4 | Completed | Bayer | Aug 9, 2017 | 560 |
| NCT02581891Macular Degeneration · Australia, Canada, France and more | 4 | Completed | Bayer | Apr 26, 2019 | 287 |
| NCT02540954Macular Degeneration · Austria, Canada, Czechia and more | 3 | Completed | Bayer | Dec 24, 2019 | 336 |
| NCT02418754Neovascular Age-Related Macular Degeneration · United States, Japan | 2 | Terminated | Regeneron Pharmaceuticals | Aug 17, 2016 | 505 |
| NCT02396316Glaucoma, Neovascular · Japan | 3 | Completed | Bayer | Jun 16, 2016 | 54 |
| NCT02305238Wet Macular Degeneration · Japan | 4 | Completed | Bayer | Dec 22, 2016 | 288 |
| NCT02120950Neovascular Macular Degeneration · Australia, Germany, Hong Kong and more | 4 | Completed | Bayer | Aug 12, 2016 | 333 |
| NCT01969708Retinal Vein Occlusion · United States | 3 | Completed | the-emmes-company-llc | Nov 2016 | 362 |
| NCT01955629Colorectal Cancer Metastatic · Italy | 2 | Terminated | Sanofi | Mar 2015 | 4 |
| NCT01882868Colorectal Cancer Metastatic · Japan | 2 | Completed | Sanofi | Aug 2015 | 62 |
| NCT01783886Macular Edema · China, Hong Kong, Korea, Republic of and more | 3 | Completed | Bayer | Mar 2015 | 381 |
| NCT01722045Macular Degeneration · United States | 4 | Completed | Regeneron Pharmaceuticals | Sep 2015 | 154 |
| NCT01661270Colorectal Cancer Metastatic · China, Hong Kong, Japan and more | 3 | Completed | Sanofi | Oct 2014 | 332 |
| NCT01670721Colorectal Cancer Metastatic · France | 3 | Completed | Sanofi | Jun 2015 | 175 |
| NCT01571284Colorectal Cancer Metastatic · United States, Belgium, Brazil and more | 3 | Completed | Sanofi | Jan 31, 2017 | 781 |
| NCT01521559Retinal Vein Occlusion · United States, Canada, Japan | 3 | Completed | Regeneron Pharmaceuticals | Aug 2013 | 183 |
| NCT01512966Macular Edema · Japan | 3 | Completed | Bayer | Sep 2013 | 73 |
| NCT01482910Macular Degeneration · China | 3 | Completed | Bayer | Mar 2014 | 304 |
| NCT01363440Diabetic Retinopathy · United States | 3 | Completed | Regeneron Pharmaceuticals | Jan 2013 | 466 |
| NCT01331681Diabetes Mellitus · Australia, Austria, Czechia and more | 3 | Completed | Bayer | Jun 3, 2013 | 406 |
| NCT01249664Myopia, Degenerative · Hong Kong, Japan, Korea, Republic of and more | 3 | Completed | Bayer | Feb 2013 | 122 |
| NCT01148615Neoplasms · China | 1 | Completed | Sanofi | Sep 2011 | 20 |
| NCT01012973Retinal Vein Occlusion · Australia, Austria, France and more | 3 | Completed | Bayer | Feb 2011 | 177 |
| NCT00964795Macular Degeneration · United States, Canada | 3 | Completed | Regeneron Pharmaceuticals | Aug 2013 | 323 |
| NCT00943072Macular Edema · United States, Canada, Colombia and more | 3 | Completed | Regeneron Pharmaceuticals | Oct 2010 | 189 |
How it is read
Names in the registry
- “Aflibercept”, 9 entries
- “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept”, 7 entries
- “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries
Codes read as this program: BAY865321, SCD411.
Conditions, from the studies’ own filings
- Macular Degeneration, 28 studies
- Macular Edema, 15 studies
- Colorectal Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Retinal Vein Occlusion, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.